Onglyza (Saxagliptin) and Related Side Effects

Posted on January 28, 2016

According to the Centers for Disease Control and Prevention (CDC), more than 29 million people in the United States have type 2 diabetes. That’s 9.3 percent of the population. Untreated type 2 diabetes can lead to heart disease, strokes, blindness, internal organ damage, and amputations. Fortunately, new medications are being made available that allow people with type 2 diabetes to live more comfortably. Unfortunately, some of these medications have been shown to have serious and dangerous side effects.

Onglyza, the brand name for the medication saxagliptin, is an oral medication manufactured by AstraZeneca, a Swedish-British pharmaceutical company that ranks as the seventh largest drug maker in the world. Onglyza was first approved by the Food and Drug Administration (FDA) in 2009. But, by 2013 there were serious concerns about the medication’s side effects.

After being prompted by studies in scholarly journals like the New England Journal of Medicine, the FDA reexamined Onglyza and found that people who took the drug had a significantly increased risk for all causes of mortality. That’s not a good thing to hear when you’ve been taking a medication prescribed to improve your health. But, it appears that Onglyza increases a person’s likelihood of being hospitalized for heart failure by 27 percent. Anyone taking Onglyza needs to immediately see a cardiologist to assess their condition.

If you have suffered adverse side effects or lost a loved one from taking Onglyza, you need to consult a pharmaceutical litigation attorney. Farah & Farah is fighting for drug company negligence victims nationwide. We can help you.

Put our legal team on your case by calling (800) 533-3555 for a free consultation.

  • This field is for validation purposes and should be left unchanged.